A recent study reports widespread decreases in PSA screening, prostate cancer diagnoses, and use of active treatment modalities since the 2011–2012 United States Preventive Services Task Force (USPSTF) recommendation against PSA screening. The updated 2017 USPSTF guideline, which embraces individualized decision-making, suggests the pendulum swung too far, but must not prompt a return to indiscriminate screening.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Figure reproduced from the SEER Database, National Cancer Institute.
References
Fleshner, K., Carlsson, S. V. & Roobol, M. J. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat. Rev. Urol. 14, 26–37 (2017).
Tsodikov, A. et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann. Internal Med. 167, 449–455 (2017).
Carlsson, S. V. & Roobol, M. J. What’s new in screening in 2015? Curr. Opin. Urol. 26, 447–458 (2016).
Moyer, V. A. Screening for prostate cancer: U. S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157, 120–134 (2012).
Kearns, J. T. et al. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. Cancer 124, 2733–2739 (2018).
Sammon, J. et al. Age dependent variation in the effect of physician recommendations to undergo prostate specific antigen (PSA) screening following the United States Preventive Services Task Force 2012 statement against PSA screening. J. Urol. 195, e248–e249 (2016).
Cooperberg, M. R. & Carroll, P. R. Trends in management for patients with localized prostate cancer, 1990–2013. JAMA 314, 80–82 (2015).
Loeb, S. et al. Uptake of active surveillance for very-low-risk prostate cancer in Sweden. JAMA Oncol. 3, 1393–1398 (2017).
US Preventive Services Task Force, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 319, 1901–1913 (2018).
Van der Kwast, T. H. & Roobol, M. J. Prostate cancer: draft USPSTF 2017 recommendation on PSA testing — a sea-change? Nat. Rev. Urol. 14, 457–458 (2017).
Acknowledgements
The authors sincerely thank M. Roobol for her help, feedback, and advice on the manuscript. S.V.C’s work on this article was supported in part by funds from the Sidney Kimmel Center for Prostate and Urologic Cancers, a Specialized Program of Research Excellence grant (P50-CA92629) from the National Cancer Institute (NCI) to H. Scher, a National Institutes of Health (NIH)–NCI Cancer Center Support Grant (P30-CA008748) to Memorial Sloan Kettering Cancer Center, a grant from the NCI as part of the Cancer Intervention and Surveillance Modelling Network (U01CA199338-02), and the David H. Koch Prostate Cancer Research Fund.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.V.C. has received a lecture honorarium and travel support from Astellas Pharma (unrelated to the current article). K.F. declares no competing interests.
Rights and permissions
About this article
Cite this article
Fleshner, K., Carlsson, S.V. The USPSTF screening recommendation: a swinging pendulum. Nat Rev Urol 15, 532–534 (2018). https://doi.org/10.1038/s41585-018-0062-5
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41585-018-0062-5
